Increased serum levels of interleukin-1β in the systemic circulation of patients with essential hypertension: Additional risk factor for atherogenesis in hypertensive patients?

Journal of Laboratory and Clinical Medicine

Volumn 129, Issue 3, 1997, Pages 300-308

  Dalekos, G N ^a   Elisaf, M ^a   Bairaktari, E ^a   Tsolas, O ^a   Siamopoulos, K C ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031106185     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(97)90178-5     Document Type: Article

References (55)

1. Dzielak DJ. The immune system and hypertension. Hypertension 1992;19(suppl I):I 36-I44.
2. Lefkos N, Boura P, Boudonas G, Zacharioudaki E, Efthimiadis A, Tsougas M, et al. Immunopathogenic mechanisms in hypertension. Am J Hypertens 1995;8:1141-5.
3. Suryaprabha P, Padma T, Brahmaji-Rao V. Increased serum IgG levels in essential hypertension. Immunol Lett 1984;8: 143-5.
4. Kristensen BO, Solling K. Serum concentrations of immunoglobulins and free light chains before and after vascular events in essential hypertension. Acta Med Scand 1983;13: 15-20.
5. Khraibi AA. Association between disturbances in the immune system and hypertension. Am J Hypertens 1991;4:635-41.
6. Krhraibi AA, Smith TL, Hutchins PM. Thymectomy delays the development of hypertension in Okamoto spontaneously hypertensive rats. J Hypertens 1987;5:537-41.
7. Kristensen BO, Andersen PL. Autoantibodies in untreated and treated essential hypertension. Acta Med Scand 1978; 203:55-9.
8. Schaadt O, Sorensen H, Krogsgaard AR. Association between the C3-F gene and essential hypertension. Clin Sci 1981;61:363S-365S.
9. Titkov YS, Ziskina RA, Temirov AA, Gybladze DV, Bubnova LN. HLA antigens in borderline and essential hypertension. Am J Hypertens 1993;6:885-7.
10. Gerbase-De Lima M, Ladalardo MA, Galvao De Lima JJ, Silva HB, Belloti G, Pileggi F. Essential hypertension and histocompatibility antigens: an association study. Hypertension 1992;19:400-2.
11. Kunes J, Zicha J. Association of salt sensitivity in rats with genes of the major histocompatibility complex. Hypertension 1994;24:645-7.
12. Shasha SM, Nusam D, Labin L, Kristal B, Steinberg O, Barzilai M, et al. Effect of converting enzyme inhibitor captorpril on T cell functions in essential hypertension. Nephron 1991;59:586-90.
13. Simon MR, Weinstock JV, Morrell RM, Roi LD, Howard LM. Captopril enhances in vitro human lymphocyte thymidine incorporation. Agents Action 1984;15:525-8.
14. Binderup L, Bramm E, Arrigoni-Martelli E. Captopril (SQ14225): in vitro and in vivo influence on the proliferative response of rat lymphocytes. Experimentia 1982;38: 399-401.
15. Balkwill FR, Burke F. The cytokine network. Immunol Today 1989;10:299-304.
16. Di Giovine FS, Duff GW. Interlukin-1: the first interleukin. Immunol Today 1990;11:13-20.
17. Dinarello CA, Wolff SM. The role of IL-1 in disease. N Engl J Med 1993;328:106-13.
18. Platanias LC, Vogelzang NJ. Interleukin-1: biology, pathophysiology and clinical prospects. Am J Med 1990;89:621-9.
19. Fraser JD, Straus D, Weiss A. Signal transdution events leading to T-cell lymphokine gene expression. Immunol Today 1993;14:357-62.
20. Libby P, Warner SJC, Friedman GB. Interleukin-1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988; 81:487-98.
21. Rossi V, Breviario F, Ghezzi P, Dejana E, Mantovani A. Prostacyclin synthesis induced in vascular cells by interleukin-1. Science 1985;229:174-6.
22. Dalekos GN, Elisaf M, Papagalanis N, Tzallas C, Siamopoulos KC. Elevated interleukin-1β in the circulation of patients with essential hypertension before any drug therapy: a pilot study. Eur J Clin Invest 1996;26:936-9.
23. Williams RR, Schumacher MC, Barlow GK, Hunt SC, Ware JL, Pratt M, et al. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah. Am J Cardiol 1993;72:18D-24D.
24. Tomino Y, Ozaki T, Koide H, Takahashi M, Ito K. Serum levels of interleukin-2 receptor and disease activity in patients with IgA nephropathy. J Clin Lab Analysis 1989;3: 355-9.
25. Pereira BJG, Skapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1α, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994;45:890-6.
26. Manoussakis MN, Papadopoulos GK, Drosos AA, Moutsopoulos HM. Soluble interleukin-2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol 1989;50:321-32.
27. Dalekos GN, Manoussakis MN, Goussia AC, Tsianos EV, Moutsopoulos HM. Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies and other autoantibodies in patients with ulcerative colitis. Gut 1993;34:658-64.
28. Dalekos GN, Manoussakis MN, Zervou E, Tsianos EV, Moutsopoulos HM. Immunologic and viral markers in the circulation of anti-HIV negative heroin addicts. Eur J Clin Invest 1993;23:219-25.
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
30. Elisaf MS, Bairaktari ETh, Tsolas OE, Siamopoulos KC. Lipoprotein (a) levels in diabetics on chronic hemodialysis. J Nephrol 1995;8:198-205.
31. Elisaf M, Bairaktari E, Tsolas O, Tzallas Ch, Germanos N, Koulouridis E, et al. Lipid parameters including Lp(a) in hemodialysis patients. Renal Failure 1994;16:501-9.
32. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R. Soluble interleukin-2 receptors are released from activated human lumphoid cells in vitro. J Immunol 1985;135:3172-7.
33. Ba D, Takeichi N, Kodama T, Kobayashi H. Restoration of T-cell depression and suppression of blood pressure in spontaneously hypertensive rats (SHR) by thymus grafts or thymus extracts. J Immunol 1982;128:1211-6.
34. Norman RA Jr, Dzielak DJ, Bost KL, Khraibi AA, Galloway PG. Immune system dysfunction contributes to the aetiology of spontaneous hypertension. J Hypertens 1985;3:261-8.
35. Fu MLX. Do immune system changes have a role in hypertension?. J Hypertens 1995;13:1259-65.
36. Tuttle RS, Boppana DP. Antihypertensive effect of interleukin-2. Hypertension 1990;15:89-94.
37. Pascual DW, Jin H, Bost KL, Oparil S. Interleukin-2 does not attenuate hypertension in spontaneously hypertensive rats. Hypertension 1990;16:468-71.
38. Dzielak DJ. Interleukin-2 and spontaneous hypertension. Hypertension 1991;18:171-5.
39. Benson JL, Niederkorn JY. Interleukin-1 abrogates anteriorchamber-associated immune deviation. Invest Ophthalmol Vis Sci 1990;31:2123-8.
40. Eastgate JA, Symons JA, Wood NC, Crilninton FM, Di Giovine FS, Duff GW. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 1988;2:706-9.
41. Mandrup-Poulsen T, Helqvist S, Molvig J, Wogensen LD, Nerup J. Cytokines as immune effector molecules in autoimmune endocrine disease with special reference to insulin-dependent diabetes mellitus. Autoimmunity 1989;4:191-218.
42. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, et al. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-I) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood 1991;78:1476-84.
43. Tsatsoulis A, Vlachoyiannopoulos PG, Dalekos GN, Johnson EO, Moutsopoulos HM. Increased serum interleukin-1β during treatment of hyperthyroidism with antithyroid drugs. Eur J Clin Invest 1995;25:654-8.
44. Dalekos GN, Zervou E, Tsianos EV, Moutsopoulos HM. Immunological markers (cytokines, receptors and autoantibodies) in chronic active hepatitis (CAH) due to hepatitis B virus (HBV): prognostic factors and interrelation during therapy with interferon-a (IFN-a). Gut 1995;37(suppl):A184.
45. Ku W, Thomas CE, Akeson AL, Jackson RL. Induction of interleukin-1 beta expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid. J Biol Chem 1992;267:14183-8.
46. Jeng K-CG, Fernandas G. Effect of fish oil diet on immune response and proteinuria in mice. Proc Natl Sci Counc B ROC 1991;15:105-10.
47. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, Van der Meer JWM, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-71.
48. Hansson GK. Immunological markers of atherosclerosis. Lancet 1993;341:278.
49. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986;314:488-91.
50. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Atherosclerosis 1986;6:131-8.
51. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991;64:5-15.
52. Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993;341: 255-9.
53. Andus T, Geiger T, Hirano T, Kishimoto T, Heinrich PC. Action of recombinant interleukin-6, interleukin-1β and tumor necrosis factor-α on the mRNA induction of acute phase proteins. Eur J Immunol 1988;18:739-46.
54. Nijsten MWN, De Groot ER, ten Duis JH, Klasen JH, Hack CE, Aarden LA. Serum levels of interleukin-6 and acute phase responses. Lancet 1987;2:921.
55. Dalekos GN, Tsianos EV, Moutsopoulos HM. Immunologic markers of disease activity in the circulation of patients with ulcerative colitis: high concentrations of soluble interleukin-2 receptor molecules and interleukin-6 in active disease. Eur J Intern Med 1996;7:93-8.